EQS-Adhoc: LANXESS Aktiengesellschaft: Impairment of goodwill and adjustment of at-equity book value of minority interest in Envalior
Source: EQS
EQS-Ad-hoc:
Ad hoc according to Art. 17 paragraph 1 MAR Impairment of goodwill and adjustment of at-equity book value of minority interest in Envalior During the preparation of annual financial statements for the year 2023, LANXESS identified an impairment requirement on goodwill amounting to In the course of the parallel and ongoing preparation of the financial statements at our joint venture Envalior, we also foresee the necessity of a material value reduction of our minority interest. This will likely result in a low to medium triple-digit million EUR amount. The impairment analyses are not completed and not yet finally audited. Neither the recognition of the impairment charges at LANXESS nor the reduction of the value of our minority interest have an effect on our EBITDA pre exceptionals, and are not cash relevant. LANXESS will report its results for Full Year 2023 on
Forward-Looking Statements This company release contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of Contact: Head of Investor Relations Kennedyplatz 1 50569 Köln, Deutschland Telefon: +49 221 8885-5249 Fax: +49 221 8885-4944 E-Mail: eva.frerker@lanxess.com End of Inside Information
|
Language: | English |
Company: | |
Kennedyplatz 1 | |
50569 |
|
Phone: | +49 (0)221 8885-3494 |
Fax: | +49 (0)221 8885-4944 |
E-mail: | ir@lanxess.com |
Internet: | www.lanxess.com |
ISIN: | DE0005470405 |
WKN: | 547040 |
Indices: | MDAX |
Listed: | Regulated Market in |
EQS News ID: | 1846611 |
End of Announcement |
|
1846611 27-Feb-